Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin
Open Access
- 1 May 1996
- Vol. 77 (9) , 1797-1808
- https://doi.org/10.1002/(sici)1097-0142(19960501)77:9<1797::aid-cncr7>3.0.co;2-9
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposideInternational Journal of Cancer, 1994
- Reduced levels of topoisomerase II? and II? in a multidrug-resistant lung-cancer cell lineCancer Chemotherapy and Pharmacology, 1994
- Cellular accumulation of the anticancer agent cisplatin: A reviewBritish Journal of Cancer, 1993
- High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.Proceedings of the National Academy of Sciences, 1992
- Current status of etoposide in the management of small cell lung cancerCancer, 1991
- Characterization of an etoposide-resistant human small-cell lung cancer cell lineCancer Chemotherapy and Pharmacology, 1990
- Overexpression of Metallothionein Confers Resistance to Anticancer DrugsScience, 1988
- VP-16 and cisplatin as first-line therapy for small-cell lung cancer.Journal of Clinical Oncology, 1985
- Charles F. Kettring prize. Fundamental studies with cisplatinCancer, 1985
- Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.Journal of Clinical Oncology, 1985